Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance

Diabetic Medicine

Volumn 29, Issue 3, 2012, Pages 359-365

  Yang, H B ^a   Zhao, X Y ^a   Zhang, J Y ^a   Du, Y Y ^a   Wang, X F ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adiponectin; Coronary borderline lesions; Impaired glucose tolerance; Pioglitazone

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTRAVASCULAR ULTRASOUND; MALE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; C-REACTIVE PROTEIN; CORONARY VESSELS; ENDOTHELIN-1; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; REMISSION INDUCTION; THIAZOLIDINEDIONES; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84863119468     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03458.x     Document Type: Article

References (23)

1. Niijima Y, Hashimoto K, Shimizu H, Tsuchiya T, Yamada M, Ohshima K et al. Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet Med 2010; 27: 1430-1435.
2. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996; 19: 1-7.
3. Takagi T, Yoshida K, Akasaka T, Kaji S, Kawamoto T, Honda Y et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in non-diabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 731-738.
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type2 diabetes (UKPDS35): prospective observational study. Br Med J 2000; 321: 405-412.
5. Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 2010; 21: 138: 157-165.
6. Rzeczuch K, Szajn G, Jankowska E, Kaczmarek A, Derkacz A, Porada A et al. Borderline coronary lesions may lead to serious coronary events-long-term outcome in 65 conservatively treated patients. Kardiol Pol 2005; 63: 50-57.
7. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
8. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol 2003; 23: 1333-1342.
9. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemia Syndromes) Registry. Circulation 2000; 102: 1014-1019.
10. Mather AN, Crean A, Abidin N, Worthy G, Ball SG, Plein S et al. Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010; 12: 61.
11. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 2200-2206.
12. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
13. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type2 diabetes in PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
14. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001; 104: 455-460.
15. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146: E5.
16. Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 2005; 112: 2792-2798.
17. Quinn CE, Lockhart CJ, Hamilton PK, Loughrey CM, McVeigh GE. Effect of pioglitazone on endothelial function in impaired glucose tolerance. Diabetes Obes Metab 2010; 12: 709-715.
18. Wajcberg E, Sriwijitkamol A, Musi N, DeFronzo RA, Cersosimo E. Relationship between vascular reactivity and lipids in Mexican-Americans with type2 diabetes treated with pioglitazone. J Clin Endocrinol Metab 2007; 92: 1256-1262.
19. Kobayashi H, Ouchi N, Kihara S, Walsh K, Kumada M, Ave Y et al. Selective suppression of endothelial cells apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94: e27-e31.
20. Perseghin G, Scifo P, DeCobelli F, Pagliato E, Battezzati A, Arcelloni C et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type2 diabetic patients. Diabetes 1999; 48: 1600-1606.
21. Bogacka I, Xie H, Bray G, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 2004; 27: 1660-1667.
22. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
23. Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007; 99: 718-725.